Q2 2018 13F Holders as of 6/30/2018
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207M
-
Number of holders
-
148
-
Total 13F shares, excl. options
-
30.6M
-
Shares change
-
+4.59M
-
Total reported value, excl. options
-
$1.2B
-
Value change
-
+$137M
-
Put/Call ratio
-
3.42
-
Number of buys
-
85
-
Number of sells
-
-90
-
Price
-
$39.19
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q2 2018
226 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2018.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 148 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30.6M shares
of 207M outstanding shares and own 14.76% of the company stock.
Largest 10 shareholders include BB BIOTECH AG (3.18M shares), Meditor Group Ltd (2.63M shares), Pentwater Capital Management LP (2.46M shares), Partner Fund Management, L.P. (2.46M shares), STATE STREET CORP (2.17M shares), BlackRock Inc. (1.81M shares), VANGUARD GROUP INC (1.55M shares), BOXER CAPITAL, LLC (1.38M shares), Aviva Holdings Ltd. (1.2M shares), and CREDIT SUISSE AG/ (1.09M shares).
This table shows the top 148 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.